Immuron CEO Steven Lydeamore Investor Webinar Presentation
November 13, 2023 18:00 ET
|
Immuron Limited
MELBOURNE, Australia, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite...
Immuron CEO Steven Lydeamore presented at AusBioInvest
October 30, 2023 07:21 ET
|
Immuron Limited
MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to advise our...
Immuron Announces Travelan® Clinical Study Cohort 2 commences
October 18, 2023 06:00 ET
|
Immuron Limited
Highlights: Second cohort of 34 healthy volunteers enrolled in the Travelan® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced...
Immuron achieves record quarterly Travelan® sales
October 11, 2023 06:00 ET
|
Immuron Limited
Highlights: Record quarterly Travelan® sales of $1,550,240Total sales of A$1,565,767 in Q1, FY24 $1,508,933 increase on Q1, FY23 sales130% higher than pre-pandemic period Q1, FY20 sales ...
Immuron achieves record monthly Travelan® sales
September 13, 2023 06:00 ET
|
Immuron Limited
Highlights: Record monthly Travelan® salesAustralian sales of A$1.18 M in August 2023 (7984% increase on August 2022 sales) MELBOURNE, Australia, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Immuron...
Immuron CEO, Steven Lydeamore to present at H.C. Wainwright
September 11, 2023 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our...
Immuron to present at the Military Health System Research Symposium
August 14, 2023 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that it...
Immuron Announces First Patients Enrolled in Travelan® Clinical Study
July 25, 2023 06:00 ET
|
Immuron Limited
Highlights: First cohort of 30 healthy volunteers enrolled in the Travelan® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced...
Immuron CEO, Steven Lydeamore to present at Bioshares
July 24, 2023 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, July 24, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief...
Immuron Business Update - Ateria Health launches Juvia™ in Australia
July 11, 2023 06:00 ET
|
Immuron Limited
Highlights: Ateria has launched Juvia™ containing breakthrough natural ingredient ERME™ in AustraliaNew clinical study is underway with the NHS in Swansea, Wales in people diagnosed with IBS due to...